Key Developments: Immunomedics Inc (IMMU.W)
3.27USD
23 May 2013
$0.18 (+5.83%)
$3.09
$3.08
$3.29
$3.08
2,300
1,590
$3.70
$2.26
Latest Key Developments (Source: Significant Developments)
Immunomedics Inc Announces Three New Patent Awards
Immunomedics Inc announced that it has received notice that its patent application for Delivery system for cytotoxic drugs by bispecific antibody pretargeting, will issue as US patent No. 8,435,539. This patent relates to compositions for pretargeting delivery of therapeutic agents for use with bispecific antibodies generated by the Company's DOCK-AND-LOCK (DNL) protein conjugation technology. The allowed claims under the patent cover the use of conjugates of therapeutic agents, such as SN-38, for cancer or other diseases, until the year 2026. The Company has also received notice that its patent application for Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy, will issue as US patent No. 8,435,529. The new patent covers the use of clivatuzumab and hRS7, and fragments thereof, for the treatment of pancreatic cancer and other forms of cancer. The allowed claims protect the use of yttrium-90-labeled clivatuzumab, which is being developed for the treatment of patients with advanced or metastatic pancreatic cancer, and hRS7-SN-38 until 2023. Full Article
Immunomedics Inc Announces First Results Of Labetuzumab-SN-38 In Colorectal Cancer
Immunomedics Inc announced that its antibody-drug conjugate (ADC), labetuzumab-SN-38, appears to be safe and reasonably well tolerated within a clinically effective dosage range in patients with advanced colorectal cancer. Results from this Phase I study were presented by Dr. Neil H. Segal from the Memorial Sloan Kettering Cancer Center, New York, NY. SN-38 is the active metabolite of irinotecan, which is a standard therapy for patients with metastatic colorectal cancer, but has gastrointestinal and hematologic toxicity. By targeting SN-38 directly to CEA-expressing tumors, delivery of SN-38 may be increased while mitigating systemic toxicity. Preclinical studies have shown that the antibody-drug linkage was susceptible to cleavage in serum, with 50% of SN-38 released in ~1.0 day, to a locally enhanced concentration within the tumor site. In animal models of human colorectal cancer, the ADC exhibited high anti-tumor activity. The goal of this single-arm, dose-escalation study was to determine the maximum-tolerated dose of labetuzumab-SN-38 in patients with metastatic colorectal cancer. Patients who had previously been treated with at least one prior irinotecan-containing regimen were enrolled to receive 2 doses of the ADC separated by 14 days. In the absence of unacceptable toxicity or disease progression, treatment continues for at least 24 weeks for a total of 12 cycles. Full Article
Immunomedics Inc Prices $14.0 Million Public Offering Of Common Stock
Immunomedics Inc announced that it has priced its previously announced underwritten public offering of 6,086,956 shares of common stock, at a price to the public of $2.30 per share, resulting in gross proceeds of $14.0 million. The offering is expected to close on or about February 27, 2013, subject to satisfaction of customary closing conditions. Immunomedics has granted the underwriters a thirty (30) day option to purchase up to 913,044 additional shares of common stock to cover over-allotments, if any. Oppenheimer & Co. Inc. and Cowen and Company, LLC, are acting as joint book-running managers for the proposed offering. Full Article
Immunomedics Inc Announces Proposed Public Offering of Common Stock
Immunomedics Inc announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Oppenheimer & Co. Inc. and Cowen and Company, LLC, are acting as joint book-running managers for the proposed offering. Full Article
Algeta ASA and Immunomedics Inc Initiate New Oncology Research Program to Evaluate Potential of Targeted Thorium Conjugate (TTC) Based on Immunomedics' Anti-CD22 Monoclonal Antibody
Algeta ASA (Algeta) announced that it has initiated a new research program to evaluate a Targeted Thorium Conjugate (TTC) that combines Algeta's thorium-227 alpha-pharmaceutical payload with an anti-CD22 monoclonal antibody (epratuzumab) developed by Immunomedics Inc. (Immunomedics). Epratuzumab is a humanized monoclonal antibody (mAb) that binds to the CD22 glycoprotein on the surface of B cells. Epratuzumab has been evaluated for the treatment of a variety of hematological cancers and for autoimmune diseases such as systemic lupus erythematosus (SLE). Under the terms of this agreement, Immunomedics will provide clinical-grade antibody to Algeta, which has rights to evaluate the potential of a TTC, linking thorium-227 to epratuzumab, for the treatment of cancer. Algeta will fund all preclinical and clinical development costs up to the end of phase I testing. Upon successful completion of phase I testing, the parties shall negotiate terms for a license at Algeta's request according to certain parameters now agreed upon between the companies. Payments in the first year from Algeta to Immunomedics include a signature fee, an antibody delivery milestone and payments for cGMP antibody manufacture. No further details of the agreement are disclosed. Full Article
Immunomedics Inc Develops Bispecific Antibodies For Diverse Solid Cancers
Immunomedics Inc announced the development of two bispecific, hexavalent antibodies created using the Company's patented DOCK-AND-LOCK (DNL) conjugation technology for targeted therapies of various epithelial cancers. Results from this preclinical study were presented at IBC's 9th Annual Antibody Therapeutics Conference in San Diego. DNL is a protein engineering platform technology for the rapid and facile creation of a wide variety of active biological agents designed for biotechnological and biomedical applications. The basis of DNL is in the natural interaction between two peptides called DDD (Docking and Dimerization Domain) and AD (Anchoring Domain). They are used as building blocks for the attachment of precursor proteins, or other entities, to become DNL-modules. The outcome of DNL is a new and stable agent, produced in a quantitative manner, which retains the full biological activities of its individual components. The precursor antibodies used in this preclinical study were hR1, the Company's humanized antibody against the type I insulin-like growth factor receptor (IGF-1R), hRS7, a humanized antibody targeting the trophoblast cell-surface marker (TROP-2), and hMN-15, a humanized antibody that recognizes the carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6). The expression of IGF-1R, TROP-2 and CEACAM6 are elevated in diverse epithelial cancers, making them attractive targets for antibody-based cancer therapy. Full Article
Immunomedics, Inc. Receives New Patent For Pretargeted Imaging And Therapy Of Cancer With Bispecific Antibody
Immunomedics, Inc. announced the issuance of US patent 8,168,186 for additional claims for the patent family "Therapeutic using a bispecific antibody." The allowed claims under the patent cover methods of use of bispecific antibodies for pretargeted imaging and therapy of diseases such as cancer, autoimmune disease, septic shock and infectious disease. The patent provides coverage until February 2021. Pretargeting is a new approach of antibody-directed therapy pioneered by the Company and its majority-owned subsidiary, IBC Pharmaceuticals, Inc. Full Article
Immunomedics, Inc. Announces Clinical Results Of Pretargeted Radioimmunotherapy Of Colorectal Cancer
Immunomedics, Inc. announced that colorectal cancer can be safely, specifically and rapidly targeted with TF2 bispecific antibody and a radiolabeled peptide, with limited toxicity to the patient. Results from the Phase I clinical study were reported at the 2012 Annual Meeting of the American Association for Cancer Research by investigators from the Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. TF2 is a bispecific antibody created by the Company's patented Dock-and-Lock (DNL) conjugation technology Full Article
Immunomedics, Inc. Awarded Broad Patent For Anti-CD20 And Anti-CD22 Combination Therapy
Immunomedics, Inc. announced the issuance of US patent 8,105,596, "Immunotherapy of B-cell malignancies using anti-CD22 antibodies." This patent covers therapeutic compositions comprising any combination of conjugated or unconjugated anti-CD20 and anti-CD22 antibodies, which may be administered separately or concurrently. The therapeutic compositions are of use for treating diseases such as B-cell malignancies, non-Hodgkin's lymphoma, indolent and aggressive forms of B-cell lymphoma, and acute and chronic forms of lymphatic leukemias. The patent provides coverage until 2018. Full Article
Immunomedics, Inc. And UCB S.A. Announce Restructuring Of Epratuzumab License Agreement
Immunomedics, Inc. and UCB S.A. announced that they have amended their Development, Collaboration and License Agreement for the exclusive worldwide rights to develop, market and sell epratuzumab for all autoimmune disease indications. The restructuring provides UCB with the flexibility to select a partner to sublicense its rights for certain territories. Under the terms of the amended agreement, in return for the right to sublicense, UCB returned its buy-in right for the cancer indication to Immunomedics. Immunomedics will receive a non-refundable cash payment totaling $30 million upon execution of the amendment. In the event UCB exercises its right to sublicense, Immunomedics will be entitled to receive an additional cash payment of $30 million and additional payments upon achievement of new regulatory and sales milestones pursuant to the amended Development, Collaboration and License Agreement. In addition, Immunomedics will issue to UCB a 5-year warrant to purchase one million shares of Immunomedics' common stock at an exercise price equal to $8.00 per share. Epratuzumab is currently being evaluated in two Phase III randomized, double blind, placebo-controlled, multicenter trials (EMBODY1 and EMBODY2) for the treatment of patients with moderate to severe lupus. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
